At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 60 enrolled
Drug / intervention
Durvalumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized Phase 2 Trial of Durvalumab (MEDI4736) With or Without SBRT in Clinical Stage I, II, and IIIA Non-small Cell Lung Cancer (NSCLC)
In Brief
A Phase 2 clinical trial evaluating Durvalumab and Durvalumab plus SBRT for Carcinoma, Non-Small-Cell Lung. Completed, enrolled 60 participants across 1 site.
Detailed Summary
The purpose of this study is to find out the effectiveness of the drug durvalumab (MEDI4736) with or without stereotactic body radiation therapy (SBRT) as treatment for stage I (tumors \> 2cm), II, and IIIA non-small cell lung cancer (NSCLC) prior to surgery and one year following surgery.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCarcinoma, Non-Small-Cell Lung
CountriesUnited States
CollaboratorsAstraZeneca
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedSep 2016
Enrollment StartDec 2016
Primary CompletionSep 2020
Study CompletionOct 2022
TodayJul 2026
First PostedSep 19, 2016
Enrollment StartDec 2, 2016
Primary CompletionSep 16, 2020
Study CompletionOct 4, 2022
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 9.8 years ago
Interventions
Durvalumabdrug
Intravenously
Durvalumab plus SBRTother
Intravenously plus radiotherapy